MedTrace Logo

Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.

NCT04535908 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-10-03

No results posted yet for this study

Summary

The majority of all new prostate cancer cases are diagnosed in men aged \> 70 years, with the highest incidence in men aged \> 90 years. Management options for localized prostate cancer include active surveillance in patients with low-risk disease, radical prostatectomy or external beam radiation therapy.

In previous studies, hypofractionated prostate cancer irradiation regimens have been shown to represent a highly effective treatment option for prostate cancer. However, patients aged 75 years or older were underrepresented in most trials resulting in the lack of a robust evidence base.

The proposed study will evaluate radiation-induced toxicity as well as outcome after hypofractionated external beam radiotherapy in prostate cancer patients aged 75 years or older.

Conditions

Interventions

RADIATION

Hypofractionated radiotherapy

Hypofractionated radiotherapy in prostate cancer patients

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Tanja Langsenlehner, MD · Medical University of Graz, Dept. of Therapeutic Radiology and Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-16
Primary Completion
2022-05-25
Completion
2022-05-25

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04535908 on ClinicalTrials.gov